Bullish & Foolish
Full KPTI fundamentals All 466 on the Survival Watch

KPTIKaryopharm Therapeutics Inc.

Is Karyopharm Therapeutics struggling financially?

Yes, by its own account. Karyopharm Therapeutics told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$44.5M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 3months

    If the burn speeds up

    Empty by Sep 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$55.0M

÷

Cash burned over the last 12 months

$145.8M

What Karyopharm Therapeutics told the SEC

…strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued. We plan to address the conditions that raise substantial doubt regarding our…

Karyopharm Therapeutics Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 198.4% share-count increase The company issued stock. Each share now owns 66.5% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 35% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt